Ibio SEC Filings

iBio, Inc. reported a material event filing that discloses a financing-related package of documents. The filing attaches an underwriting agreement with Leerink Partners as representative of the underwriters, forms for a pre-funded warrant and two series of warrants, a legal opinion and consent from Blank Rome LLP, and two press releases described as a launch release and a pricing release. The filing also includes the interactive cover page data file. The disclosure signals a planned securities offering structure but does not include offering size, pricing terms, or proceeds in the attached exhibit list.

iBio, Inc. filed a prospectus supplement on Form 424B5 describing a securities offering that includes pre-funded warrants, Series G and Series H warrants, and related common stock issuances. The underwriters receive a commission equal to 6.0% of aggregate gross proceeds. The filing lists outstanding and reserved equity instruments as of March 31, 2025 and August 11, 2025, including stock options (weighted-average exercise prices $5.15 and $5.92), pre-funded warrants with a $0.0001 exercise price, previously issued warrants with weighted-average exercise prices of $2.30 and $1.30, and shares reserved under the 2023 Omnibus Equity Incentive Plan. The document discusses use of proceeds, risk factors, plan of distribution, restrictions on transfers and lock-up provisions, U.S. and non-U.S. holder tax rules, and where SEC filings are incorporated by reference. The prospectus also describes iBio’s AI-driven epitope engine, capital-efficient strategy emphasizing partnerships, tech licensing, and in-house preclinical programs focused on oncology, obesity and cardiometabolic diseases.

iBio, Inc. filed a prospectus supplement for an offering that includes Series G warrants and Series H warrants (the latter issuable upon exercise of Series G warrants) and related pre-funded warrants or common stock. The underwriting fees include a 6.0% commission on aggregate gross proceeds. The document discloses outstanding equity-linked instruments as of March 31, 2025 and August 11, 2025, including stock options, restricted stock units, previously issued pre-funded warrants and warrants, and shares reserved under the 2023 Omnibus Equity Incentive Plan, which create dilution potential. The prospectus describes intended use of proceeds, risk factors (including that warrants may expire worthless), tax withholding rules for non-U.S. holders, and lists incorporated SEC filings and periodic reports. The supplement also highlights the company’s AI-based epitope engine, its capital-efficient strategy emphasizing strategic partnerships, tech licensing and advancing in-house preclinical programs.

ADAR1-affiliated investors report beneficial ownership of 1,794,055 shares of iBio, Inc., representing 9.9% of the outstanding common stock. The holding comprises 54,819 shares held directly by ADAR1 Partners, LP and 1,739,236 shares issuable upon conversion of milestone warrants held by ADAR1 Partners, LP. The filing states that 716,904 additional shares underlying milestone warrants are excluded because their exchange or exercise is subject to a 9.99% beneficial ownership limitation.

The reporting entities are ADAR1 Capital Management, LLC (investment adviser), ADAR1 Capital Management GP, LLC (general partner) and Daniel Schneeberger (manager), each disclosing shared voting and dispositive power over the 1,794,055 shares. The ownership percentage is calculated on a stated base of 16,219,281 shares outstanding.

iBio, Inc. (Nasdaq: IBIO) has filed a Form 424(b)(3) prospectus dated June 23, 2025 to register the resale of up to 11,253,370 shares of common stock. The shares correspond to the same number of shares underlying New Warrants issued in a private placement completed on April 30, 2025 under an Inducement Agreement signed April 29, 2025.

• Warrant terms: exercise price $0.86, immediately exercisable, five-year term.
• Potential company proceeds: up to approximately $9.7 million in cash should all warrants be exercised.
• Use of prospectus: enables the Selling Stockholders (and their transferees) to sell shares at market, related, or negotiated prices; iBio will not receive sale proceeds but will cover registration expenses.
• Selling mechanics: shares may be sold via underwriters, brokers, or directly in public or private transactions as detailed in the “Plan of Distribution.”
• Listing information: IBIO last traded at $0.771 on June 20, 2025, below the warrant exercise price.

The filing satisfies iBio’s contractual obligation to register the shares, preserves potential capital inflow from future warrant exercises, and signals possible dilution if the warrants are exercised. Investors should consult the “Risk Factors” section on page 5 and the company’s SEC filings for further details.

On June 24, 2025, iBio, Inc. (Nasdaq: IBIO) filed a Form 8-K to inform the market that it has released an updated corporate presentation, dated June 2025. The slide deck, furnished as Exhibit 99.1, will be used in discussions with investors, analysts and other stakeholders. The filing is made under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). iBio states that the presentation includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995 and that the company assumes no obligation to update the material. No financial results, strategic transactions or other material developments are disclosed in this report.